🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We've raised $6.6M to advance our CHM CDH17 CAR-T & CORE-NK trials. The two-tranche placement received strong support from institutional, professional, & sophisticated investors, including cornerstone backing from a US-based family office. More info: app.sharelinktechnologies.com/announcement/a… $CHM

CEO Dr Rebecca McQualter will host an investor webinar and provide an update following our $6.6 million capital raising. 🗓 When: 10:30 am AEST, Thursday 22 May 2025 📲 Register here: us02web.zoom.us/webinar/regist… Questions can be submitted to [email protected] $CHM

We've advanced our CHM CDH17 Phase 1/2 trial to Dose Level 2 (150M CAR-T+ cells), following a clean safety profile and early signs of activity at Dose Level 1 (50M cells). Two patients with advanced gastrointestinal cancers achieved stable disease. app.sharelinktechnologies.com/announcement/a… $CHM

Presentation to investor webinar: May 2025 View the full $CHM Presentation here: app.sharelinktechnologies.com/announcement/a… #ASX #Biotech

📰Chimeric advances CHM CDH17 clinical trial to Dose Level 2 | Media coverage by PharmaDispatch. biotechdispatch.com.au/news/blinklab-… $CHM #Chimeric #Biotech

We're attending #ASCO 2025. Chimeric Therapeutics ASX: CHM will be on the ground in Chicago to connect with the global oncology community and share updates on our 3 novel cell therapies and 4 Clinical Trials. asco.org/annual-meeting $CHM

We’ve had a busy few months at Chimeric Therapeutics ASX: CHM. In case you missed the investor webinar, our CEO Dr Rebecca McQualter shares a personal update on recent progress across clinical development and financials. Read the full letter: app.sharelinktechnologies.com/announcement/a… $CHM #Biotech #ASX

Meet the Team: Stephanie H. Astrow, PhD, MBA – Chief Scientific Officer. Stephanie is an innovative and highly accomplished scientist and business executive, with experience spanning cellular immunotherapy, clinical diagnostics, and personalised medicine. $CHM

Meet the Team: Dr. Agathe Bourgogne - Executive Director CMC: Head of Manufacturing At Chimeric Therapeutics ASX: CHM, Agathe leads the manufacturing of our clinical programs, ensuring the reliable and scalable delivery of our cell therapies from the lab to first-in-human trials. $CHM

We’ve been featured in the latest Bioshares report following our $6.6M placement and encouraging clinical progress. Bioshares has added Chimeric to its Model Portfolio with a “Speculative Buy – Class B” rating. $CHM #Biotech

We’ve received US FDA Fast Track for $CHM CDH17 in GEP-NETs, recognising its potential in hard-to-treat cancers. Five patients treated, seven manufacturing runs completed. app.sharelinktechnologies.com/announcement/a… 📸 NET Research Foundation CEO Elyse Gellerman, CMO Jason Litten & CEO Dr Rebecca McQualter

Chimeric Therapeutics gains FDA fast-track approval for CHM CDH17 gastrointestinal cancer candidate | Media coverage by Small Caps. smallcaps.com.au/chimeric-thera… $CHM #Chimeric #SmallCaps #Biotech #ASXNews

We've secured a $2.5 million advance from Endpoints Capital, under a funding facility secured against our anticipated FY25 Research and Development Tax Incentive. The funds will support our clinical trial pipeline and general working capital. More: app.sharelinktechnologies.com/announcement/a… $CHM

We're proud to share this NETRF video featuring Dr Jennifer Eads, lead investigator for our $CHM CDH17 trial, the first CAR T trial in NETs, built on a decade of foundational work at UPenn. Watch here: youtu.be/1injNZEVTZA?si…

We’re looking forward to our Chief Medical Officer, Dr Jason Litten, presenting at BIO 2025 in Boston. Jason will be speaking on Wednesday, 18 June at 11:30 AM in Room 153A. More info: convention.bio.org/bio-2025 $CHM #BIO2025 #CellTherapy #CancerResearch #ChimericTherapeutics #ASX

We’ve completed Dose Level 1 enrolment in our $CHM CDH17 trial. Translational data shows CAR-T cells expanded and persisted in all patients, with measurable persistence up to 6 months in two cases of stable disease. app.sharelinktechnologies.com/announcement/a… #ASX #Biotech

Today on #RareCancerDay, we recognise patients living with GEP-NETs – rare tumours of the GI tract and pancreas. Chimeric is developing CHM CDH17, a first-in-class CAR T cell therapy targeting these hard-to-treat cancers. #RareCancersAwarenessDay $CHM

We've appointed Prof. H. Miles Prince AM as Non-Executive Director. An internationally recognised leader in haematology and CAR-T trials, his expertise strengthens our clinical and strategic direction as we advance cell therapies for cancer. app.sharelinktechnologies.com/announcement/a… $CHM

“We’re excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space,” CEO Dr Rebecca McQualter told @Stockhead. stockhead.com.au/health/asx-bio… $CHM #Chimeric #Biotech

Our CEO Dr Rebecca McQualter, will present at the AU CAR-T Showcase on Tuesday, 12 August 2025. Join us at 4:15 PM for a 4:30 PM start at FB Rice, Lvl 33, 477 Collins Street, Melbourne, to hear about the latest developments in CAR-T therapies. Register: [email protected] $CHM